KRAS G12D
Clinical trials for KRAS G12D explained in plain language.
Never miss a new study
Get alerted when new KRAS G12D trials appear
Sign up with your email to follow new studies for KRAS G12D, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New pill targets Hard-to-Treat cancers: early trial recruits 554 patients
Disease control Recruiting nowThis study tests an experimental oral drug called S241656 (BDTX-4933) in people with advanced solid tumors that have certain genetic changes (KRAS, BRAF, or other RAS/MAPK mutations). The trial has two parts: first, finding a safe dose, then testing how well it works alone or wit…
Matched conditions: KRAS G12D
Phase: PHASE1, PHASE2 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Jun 23, 2026 23:32 UTC
-
New hope for rare blood vessel disorders: targeted drugs enter trial
Disease control Recruiting nowThis phase 2 trial is testing two targeted drugs—alpelisib and mirdametinib—in people with vascular malformations (abnormal blood vessels). The study enrolls 50 participants aged 2 and older, split into two groups based on whether their malformations are slow-flow or fast-flow. E…
Matched conditions: KRAS G12D
Phase: PHASE2 • Sponsor: Murdoch Childrens Research Institute • Aim: Disease control
Last updated Jun 23, 2026 11:59 UTC
-
New immunotherapy option for High-Risk pancreatic cancer patients
Disease control AVAILABLEThis expanded access program offers ELI-002 7P, an immunotherapy, to pancreatic cancer patients with specific KRAS or NRAS gene mutations who have had their tumor removed but are at high risk of the cancer coming back. The treatment aims to stimulate the immune system to target a…
Matched conditions: KRAS G12D
Sponsor: Elicio Therapeutics • Aim: Disease control
Last updated Jun 17, 2026 12:05 UTC
-
New pill targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called BBO-11818 in people with advanced cancers that have a KRAS mutation, including lung, pancreatic, and colorectal cancers. The main goals are to check safety and find the best dose, while also seeing if the drug can shrink tumors. Abou…
Matched conditions: KRAS G12D
Phase: PHASE1 • Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) • Aim: Disease control
Last updated Jun 08, 2026 13:11 UTC